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Structure–activity relationshipThe novel guanidine compounds trans-[Pt(NH2Me)2{NH=C(NHMe)NR}2](Cl)2 (R = NEt2 [7], NC5H10 [8])
(trans-7,8) were synthesized by the nucleophilic addition of methylamine to dialkylcyanamide ligands of the
push–pull nitrile complexes trans-[PtCl2(RCN)2] (R = NEt2, NC5H10). In vitro cytotoxicity tests conducted
for the entire series of the guanidine complexes, i.e. trans-7,8, the neutral cis- or trans-[PtCl2{NH=C(NH2)R}2]
(cis-1–3 and trans-1–3) and the cationic cis- or trans-[Pt(NH3)2{NH=C(NH2)R}2](Cl)2 (cis-4–6 and trans-4–6)
(R = NMe2 [1,4], NEt2 [2,5], NC5H10 [3,6]) in two human cancer cell lines, CH1 (ovarian carcinoma) and SW480
(colon cancer), conﬁrmed that the cytotoxicity of several trans-conﬁgured (trans-3,6) complexes is higher than
that of cis-congeners (cis-3,6). Cellular platinum levels were analyzed by inductively coupled plasmamass spec-
trometry upon treatment of SW480 cells, revealing a dependence of cellular accumulation on the geometrical
isomerism and the steric hindrance of the variable substituent R on the guanidine ligand. DNA interactions of
selected guanidine complexes were studied in order to ﬁnd hints for the possible reasons for their different
activities. Changes induced to the electrophoretic mobility of a dsDNA plasmid conﬁrmed the potency of the
guanidine complexes (e.g. trans-1,3,5,6 and cis-1,3,4) to signiﬁcantly alter DNA secondary structure, indicating
DNA as a possible critical target of these compounds.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. 1. Introduction
The three globally approved platinum based complexes – cisplatin,
oxaliplatin, and carboplatin – play a major role in cancer chemotherapy
[1]. The fundamental complex of the class is cis-[PtCl2(NH3)]2 (cis-DDP,
cisplatin), which is supposed to exert its antitumor activity by distorting
DNA functionality [2,3]. However, along with a high curative potential
in certain malignancies, there are principal drawbacks of cisplatin and
its analogs such as undesirable side effects, mutagenic effects, and
the occurrence of drug resistance [4–6]. The success of cisplatin has
imposed a certain direction on the investigation of novel substances,ganic Chemistry, University of
.: +43 1 4277 52610; fax: +43
“Translational Cancer Therapy
090 Vienna, Austria. Tel.: +43
Jakupec),
. All rights reserved.Open access underin the ﬁrst instance excluding compounds that may possess different
andmaybe uniquemodes of action. Todaymany active non-classic com-
pounds, which violate the long accepted structure–activity relation-
ships [7] for platinum based drugs [8–11], are known from the
literature. Above all, the presence of twomonodentate or one bidentate
exchangeable ligand(s) (commonly called leaving groups) coordinated
in cis-geometry has been declared a requirement for antitumor activity.
The signiﬁcantly lower cytotoxicity of transplatin compared to that of
cisplatin in vitro as well as its inactivity in vivo has been ascribed to
its disfavored chelation reactions with DNA molecules due to the
trans-standing leaving groups [12].
Nevertheless, numerous exceptions from the classic rules have been
found in the last several years. The classes of trans-complexes exhibiting
at least equal or even higher cytotoxicity than the corresponding cis-
isomers are platinum(IV) species bearing pyridine-like ligands [13],
platinum(II) complexes with iminoethers [14,15], and platinum(II)
compounds featuring piperidine or piperazine ligands [16,17]. For the
above groups, antitumor activity was conﬁrmed by in vivo experiments
in mice models. Other non-classic complexes are platinum(II) oxime
species [18,19], compounds bearing planar [20] and aliphatic amines
[21], complexes containing various phosphoric groups [22], and com-
plexes featuring the acetimine ligand [23]. Most of the listed platinum
species are equally or even more cytotoxic than cisplatin. CC BY-NC-ND license. 
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prepared by the nucleophilic addition of ammonia to the push–pull
dialkylcyanamide ligands in cis- and trans-[PtCl2(RCN)2] (R = NMe2,
NEt2, NC5H10). Neutral complexes cis-1–3 and trans-1–3 as well as
cationic complexes cis-4–6 and trans-4–6, which contain NH3 instead
of Cl− ligands, were synthesized and characterized previously [24].
Additionally, we have now synthesized the cationic guanidine com-
pounds trans-[Pt(NH2Me)2{NH=C(NHMe)NR}2](Cl)2 (R = NEt2,
NC5H10) (trans-7,8) by the nucleophilic addition of methylamine to
dialkylcyanamides in the platinum(II) complexes trans-[PtCl2(RCN)2]
(R = NEt2, NC5H10). Compounds trans-7,8were puriﬁed and character-
ized by elemental analyses, electrospray ionization mass spectrometry
(ESI-MS), IR, 1H and 13C{1H} NMR spectroscopy. The biological activity
of the entire series of the guanidine species (cis-1–6 and trans-1–8)
was studied, and the obtained results give novel insights into potential
of non-classic platinum drugs.
2. Experimental section
2.1. Synthesis of starting complexes and cis/trans-1–6
Solvents were obtained from commercial sources and used with-
out further puriﬁcation and drying. The starting dialkylcyanimide
platinum(II) complexes, [PtCl2(Et2NCN)2] and [PtCl2(C5H10NCN)2],
were prepared according to the published methods [25] as mixtures
of cis- and trans-isomers that were separated by column chromatog-
raphy on SiO2 Merck 60 F254 (eluent: Me2CO:CHCl3 = 1:10, v/v).
The synthesis of complexes cis/trans-1–6 was reported by Tyan
et al. [24].
2.2. Synthesis of complexes trans-7,8
Complexes were synthesized via the amination of undried CH2Cl2
solutions (2 mL) of trans-[PtCl2(Et2NCN)2] (0.205 mmol; 120 mg)
and trans-[PtCl2(C5H10NCN)2] (0.213 mmol; 130 mg) by gaseousN
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Scheme 1. Synthesis of guanidinmethylamine (10-fold excess) for 4–5 h at room temperature (RT),
which resulted in the formation of the cationic trans-[Pt(NH2Me)2
{NH = C(NHMe)NR}2](Cl)2 (R = NEt2, NC5H10) (trans-7,8) species
(Scheme 1). Discoloration of the initially yellow solutions and the pre-
cipitation of the colorless products were observed. The precipitates
were separated by ﬁltration and dried in air at RT; yields 87%
(125.2 mg) and 83% (135.2 mg) for trans-7,8, respectively. Both com-
plexes are well soluble in water and cell culture medium (viz. MEM).
trans-[Pt(NH2Me)2{NH = C(NHMe)N(Et)2}2]Cl2 (7) Anal. Calcd for
C14H40N8Cl2Pt: C, 28.67; H, 6.87; N, 19.11. Found: C, 28.42; H, 6.90; N,
19.37. ESI+-MS,m/z (M refers to themolecularweight of C14H40N8Cl2Pt):
1137.49 [2M–Cl]+ (calc.: 1137.50), 551.26 [M–Cl]+ (calc.: 551.27), 520.22
[M–Cl–NH2Me]+ (calc.: 520.22), 452.20 [M–2NH2Me–2Cl–H]+
(calc.: 452.20), 257.65 [M–2Cl]2+ (calc.: 257.65). IR (KBr, selected
bands, cm−1): 3269 (m), 3194 (m), 3092 (m), ν(N\H); 2970 (m-w),
2936 (m-w), 2888 (m-w), ν(C\H); 1591 (s), ν(C_N); 1282 (m-w),
ν(C\N). 1H NMR [CDCl3, δ]: 7.43 (s, br, H, _NH\), 5.58 (s, br, H,
\NH\), 4.88 (s, br, 2H, \NH2\), 3.31 (q, 3JHH 6.9 Hz, 4H,\CH2\ [in
NEt2]), 3.01 (d, 3JHH 4.5 Hz, 3H, \CH3 [in NHMe]), 2.30 (t, 3JHH 6.2 Hz,
3H, \CH3 [in NH2Me]), 1.14 (t, 3JHH 6.9 Hz, 6H, \CH3 [in NEt2]).
13C{1H} NMR [CDCl3, δ]: 164.72 (C_N), 43.61 (\CH2\ [carbons
in NEt2]), 33.18, 31.62 (\CH3 [carbons in NHMe/NH2Me]), 13.53
(\CH3 [carbons in NEt2]).
trans-[Pt(NH2Me)2{NH = C(NHMe)N(C5H10)}2]Cl2 (8) Anal. Calcd
for C16H40N8Cl2Pt: C, 31.47; H, 6.60; N, 18.35. Found: C, 31.14; H,
6.71; N, 18.46. ESI+-MS, m/z (M refers to the molecular weight of
C16H40N8Cl2Pt): 1185.49 [2M–Cl]+ (calc.: 1185.50), 575.26 [M–Cl]+
(calc.: 575.27), 544.22 [M–Cl–NH2Me]+ (calc.: 544.22), 538.27 [M–2Cl–
H]+ (calc.: 538.27), 269.64 [M–2Cl]2+ (calc.: 269.65). IR (KBr, selected
bands, cm−1): 3418 (m), 3277 (m), 3089 (m), ν(N\H); 2936 (m-w),
2854 (m-w), ν(C\H); 1584 (s), ν(C_N); 1256 (m-w), ν(C\N).
1H NMR [CDCl3, δ]: 7.62 (s, br, H, _NH\), 5.42 (s, br, H, \NH\),
4.81 (s, br, 2H, \NH2\), 3.22 (s, 4H, α-CH2\ [in NC5H10]), 2.95 (d,
3H, \CH3 [in NHMe]), 2.28 (t, 3H, 3JHH 6.3 Hz, \CH3 [in NH2Me]),
1.59 (s, br, 6H, β, γ-CH2\ [in NC5H10]). 13C{1H} NMR [CDCl3, δ]:
166.07 (C_N), 49.55 (α-CH2\ [carbons in NC5H10]), 32.96, 31.368MeNH2, MeNHNC5H10
7MeNH2, MeNH           NEt2
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in NC5H10]).
2.3. Characterization of trans-7,8
Elemental analyses were carried out at the Department of Organic
Chemistry, Saint Petersburg State University on a 185 V Hewlett
Packard Carbon Hydrogen Nitrogen Analyzer. Infrared spectra
(4000–400 cm−1) were recorded on a Shimadzu FTIR-8400S spectro-
photometer in KBr pellets.
1H and 13C{1H} NMR spectra were measured on a Bruker DPX 400
spectrometer at ambient temperature. Chemical shifts were measured
relatively to the signals of the solvent CDCl3 (7.27 in the 1HNMR spectra
and 77.4 in 13C{1H} NMR spectra).
Electrospray mass spectra were recorded on a Bruker micrOTOF in-
strument, equipped with an electrospray ion source type (ESI− or
ESI+). For the mass spectrometric studies samples were dissolved in
MeCN with an upper boundary of the concentration of 5–15 mg/mL.
The resulting solution was supplied to the electrospray capillary by
using a KDScientiﬁc syringe pump. The voltage generated at an elec-
trode and the voltages on the capillary were −500 V and −4500 V
(ESI+-MS) or 3500 V (ESI−-MS), respectively. The sample solution
ﬂow through the electrospray capillary was 3 mL/min. The output volt-
age of the capillary was ±70 or ±150 V. ESI+ and ESI− mass spectra
were recorded in the range of 50 to 3000 m/z. Drying gas pressure in
the spray was 0.4 bar, ﬂow rate and temperature of the drying gas
were 4.0 L/min and 180 °C, respectively.
2.4. Cell lines and growth conditions
Two human cancer cell lines were used for the studies, viz. CH1
(ovarian carcinoma) and SW480 (colon carcinoma), kindly provided
by Lloyd R. Kelland (CRC Centre for Cancer Therapeutics, Institute of
Cancer Research, Sutton, UK) and Brigitte Marian (Institute of Cancer
Research, Department of Medicine I, Medical University of Vienna,
Austria), respectively. Cells were grown in 75 cm2 culture ﬂasks (Iwaki/
Asahi Technoglass, Gyouda, Japan) as adherent monolayer cultures in
complete medium [i.e., minimal essential medium (MEM) supplement-
ed with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyru-
vate, 4 mM L-glutamine, and 1% nonessential amino acids from 100×
ready-to-use stock (all purchased from Sigma-Aldrich, Austria)]. Cell
cultures were incubated at 37 °C in a moist atmosphere containing
5% CO2.
2.5. Cytotoxicity in cancer cell lines
The cytotoxic activity of test compounds was determined by using
the colorimetric microculture MTT assay (MTT = 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). CH1 and SW480
cells were collected from culture ﬂasks by trypsinization and seeded
in 100 μL aliquots in MEM into 96-well microculture plates (Iwaki/
Asahi Technoglass, Gyouda, Japan) in cell densities of 3 × 103, 1 × 103
and 2.5 × 103 cells per well, respectively. After 24 h preincubation of
the cells, the test compounds were dissolved and serially diluted in
MEM, and 100 μL of solution were added per well. After continuous ex-
posure for 96 h, drug solutions were replaced with 100 μL RPMI 1640
culture medium (supplemented with 10% heat-inactivated fetal bovine
serum and 2 mM L-glutamine) plus 20 μL MTT solution in phosphate-
buffered saline (5 mg/mL). After incubation for 4 h, the RPMI/MTTmix-
tures were removed, and the formazan crystals formed in viable cells
were dissolved in 150 μL of DMSO perwell. Optical densities weremea-
sured at a wavelength of 550 nmwith amicroplate reader (Tecan Spec-
tra Classic), using a reference wavelength of 690 nm to correct for
unspeciﬁc absorption. The quantity of viable cells was expressed by
comparison of treated microcultures to untreated control microcul-
tures, and 50% inhibitory concentrations (IC50) were calculated fromconcentration-effect curves by interpolation. Evaluation is based on
means from at least three independent experiments, each comprising
six microcultures per concentration level.
2.6. Cellular accumulation experiments
To determine the intracellular drug concentration, themethod thor-
oughly described in Egger et al. [26] was used. Brieﬂy, cells were seeded
in 6-well plates (Iwaki/Asahi Technoglass, Gyouda, Japan) in a volume
of 2.5 mL complete medium (MEM) in densities of about 3 × 105 cells
per well. Cell microcultures were incubated in a moist atmosphere at
37 °C for 24 h prior to 2 h exposure to the test compounds. The number
of viable cells was determined by using trypan blue (Sigma-Aldrich,
Austria) exclusion in parallel microcultures during the exposure period.
After exposure, the mediumwas removed, cells were washed with PBS
and then lyzed with 0.5 mL sub-boiled HNO3 (conc.) per well for 1 h.
Cellular accumulation experiments in the non-adherent state were
performed alternativelywith those compounds that have amuch stron-
ger afﬁnity to the polystyrene of the culture plates than to the cells
(since non-adherent cells can easily be collectedwithout detachingma-
nipulations and transferred into other vessels prior to digestion, there is
no need for measuring adsorption blanks). For this purpose, cells were
harvested from the culture ﬂasks, counted and transferred into 15 mL
tubes in amounts of approximately 3 × 105 cells per tube (2.5 mL of
cell suspension), which corresponds with the cell density in adherent-
state experiments. Cells were exposed to the drugs for 2 h immediately
after transfer, and the samples were shaken carefully every 15 min to
keep the cells in suspension. After exposure, the cells were centrifuged,
the mediumwas removed, cells were washed with PBS and then trans-
ferred into 1.5 mL tubes where they were lyzedwith 0.5 mL sub-boiled
HNO3 (conc.) per tube for 1 h. In all experiments, Pt concentrations
were quantiﬁed by inductively coupled plasma mass spectrometry
(ICP-MS) in the presence of 0.5 μM In standard. Results are based on
three independent experiments, each consisting of three replicates.
2.7. Alterations in DNA secondary structure
To assess drug–DNA interactions, the pPUC19 DNA plasmid
(Fermentas, UK) was incubated with test compounds for different
periods of time (i.e., from 15 min to 3 h). Electrophoresis was per-
formed in 1% agarose gel for 2 h at 80 V and 55 mA in 1× TBE buffer
(0.45 M Tris borate, 0.01 M EDTA, pH 8.3, purchased from Eppendorf
AG, Germany). PEQLAB electrophoresis chambers were used. Staining
was performed in ethidium bromide (EtBr) solution in 1× TBE
(0.2 μg/mL) for 20 min. Images were taken under UVE light in the
GelDoc-It Imaging System (UVP).
3. Results
3.1. Cytotoxicity in cancer cells
A cisplatin sensitive ovarian carcinoma cell line (CH1) and intrinsi-
cally cisplatin resistant (but oxaliplatin sensitive) colon carcinoma cell
line (SW480) were chosen for the experiments. The inhibitory potency
of complexes cis-1–6 and trans-1–8 on proliferation and viability of
these human cancer cells was characterized by using the spectrophoto-
metric MTT assay (Table 1), and the following structure-activity rela-
tionships were inferred from the data.
Cytotoxicities of the trans-conﬁgured complexes are mostly not
higher than those of the corresponding cis-congeners with a few
notable exceptions. The most active compound in the cell line SW480
is trans-3 with the most sterically encumbered substituent R (R =
NC5H10, IC50 = 19 μM). Cytotoxic potency of this compound exceeds
that of cis-3, which is one of the most active complexes with cis-
conﬁguration (cis-3, IC50 = 32 μM).
Table 1
IC50 values (μM; mean ± standard deviation) of cis-1–6 and trans-1–8 in two cancer cell lines (CH1 and SW480).
1 2 3 4
cis trans cis trans cis trans cis trans
CH1 2.7 ± 0.4 5.2 ± 1.1 3.0 ± 0.4 23 ± 4 4.4 ± 0.8 7.4 ± 1.3 21 ± 6 210 ± 70
SW480 36 ± 2 36 ± 10 32 ± 7 62 ± 5 32 ± 5 19 ± 3 370 ± 40 N640
5 6 7 8 cisplatin transplatin
cis trans cis trans trans trans
CH1 39 ± 12 25 ± 4 40 ± 2 8.2 ± 2 140 ± 40 330 ± 60 0.14 ± 0.03 15 ± 2
SW480 42 ± 6 110 ± 20 46 ± 2 55 ± 1 241 ± 3 N640 3.3 ± 0.4 19 ± 3
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lower IC50 values in CH1 cells than the corresponding cis-isomers. Fur-
thermore, cytotoxic potencies of trans-4–6 correlate with the steric hin-
drance of substituents R, with bulkier groups (R = NC5H10 N NEt2 N
NMe2) yielding higher cytotoxicities in both cell lines, approaching
or even exceeding that of transplatin (Fig. 1). However, the cis-
conﬁgured complexes are by one to two orders ofmagnitude less potent
than cisplatin.
In general, cytotoxicity of neutral cis-/trans-1–3 is higher than that of
cationic guanidine complexes cis-/trans-4–6, which conﬁrms the higher
potency of molecules containing labile ligands. However, the cytotoxic
potency of trans-6 is reaching that of the corresponding neutral couple
cis-/trans-3, despite the lack of distinctly labile ligands.
Cationic guanidine complexes trans-7,8 – derived from the nucleo-
philic addition of MeNH2 to the metal-bound dialkylcyanamides – have
shown a rather moderate level of cytotoxicity in both cell lines,
apparently indicating that the methyl substituted am(m)ine ligands
are less favorable for the cytotoxic potency of guanidine platinum
complexes.
3.2. Cellular accumulation
In order to ﬁgure out whether cytotoxicity correlates with cellular
accumulation of the compounds, cellular platinum levelswere analyzed0
20
40
60
80
100
pe
rc
en
ta
ge
 o
f v
ia
bl
e 
ce
lls
trans-4 trans-5 trans-6 transplatin
0
20
40
60
80
100
concentration, µM 
pe
rc
en
ta
ge
 o
f v
ia
bl
e 
ce
lls
1 10 100 1000
1 10 100 1000
Fig. 1. Concentration-effect curves of trans-4,5,6 and transplatin in CH1 (top) and SW480
(bottom) cells. Cytotoxicity correlates with the steric hindrance of the substituents R
(R = NMe2 in trans-4, NEt2 in trans-5, NC5H10 in trans-6 and cis-6).
Curves for transplatin are taken from Ref. [10].by ICP-MS upon treatment of SW480 cells for 2 h with 50 μM of cis-
1,3,4,6, trans-1,3,4,6,7, as well as the reference compounds, viz. cisplatin
and transplatin (Fig. 2).
The dependence of cellular accumulation on coordination geometry
in the case of neutral guanidine complexes (cis-1,3, trans-1,3) correlates
well with the reference couple (cisplatin, transplatin), with trans-
conﬁgured compounds being accumulated more efﬁciently by the
cells. However, the cytotoxicities of the trans-conﬁgured (trans-1,3)
neutral guanidine complexes in SW480 cells are comparable or only
slightly superior to those of their cis-isomers (cis-1,3). For the cationic
guanidine complexes (cis-4,6, trans-4,6) the reverse relationship was
observed.
Experiments with adherent cell microcultures posed the problem
that a few substances (cis-4, trans-4) displayed much higher afﬁnity to
the plastics of the dishes then to the cells. In these cases, the wells
used as adsorption/desorption controls, which were exposed to the
test substances, but were free from cells showed a high concentration
of Pt. The latter indicates that substantial amounts of compounds were
adsorbed to the surface of the wells and became randomly desorbed
by the preparation, resulting in high deviations (Fig. 2). To overcome
this problem, we performed experiments with non-adherent cells.
This avoided desorption of adsorbed compounds by separating the
exposure and lyzing steps from other by using using different vessels.
The modiﬁed experiment gave an appropriate repeatability, and the
values obtained for cisplatin and transplatin correspond well with those
measured in the adherent state. For compounds cis-4 and trans-4, the
same dependence on geometric isomerism, as in case of cis-/trans-6,
was observed (Fig. 3).
3.3. Alteration of DNA secondary structure
Since the difference in cytotoxic potency between cisplatin and
transplatin has been ascribed to different capacities of forming particu-
lar DNA cross-links, DNA interactions of selected compounds were
studied to ﬁnd hints for possible reasons for their different activities.
For this purpose, effects on electrophoreticmobility of a dsDNAplasmid,
indicating the impact on DNA secondary structure in cell-free condi-
tions, were investigated. The pUC19 plasmid was exposed to com-
pounds for different time periods (15 min–3 h), and then the mobility
of DNA was studied in an agarose gel. In particular, the retardation of
the supercoiled form of the plasmid in the gel allows making conclu-
sions about the capacity of forming adducts that lead to local unwinding
of DNA. Monofunctional and bifunctional adducts can result in retarda-
tion of theplasmidDNA (due to highermass, decrease of positive charge
or untwisting of the supercoiled form) or in acceleration of the plasmid
DNA due to bending and/or twisting. The composite action of all these
factors leads to the observed pattern (Fig. 4).
Among all tested compounds, only trans-4 does not alter the electro-
phoretic mobility of the plasmid signiﬁcantly, suggesting that if this
compound interacts with DNA at all it does so without altering DNA
secondary structure, excluding all forms of cross-links. This is consistent
with the lack of marked cytotoxicity in the MTT assay (Table 1). All the
other drugs are capable of DNA binding to varying degrees. Compound
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37A.A. Legin et al. / Journal of Inorganic Biochemistry 133 (2014) 33–39cis-1 causes a more pronounced retardation of electrophoretic migra-
tion of the supercoiled plasmid after shorter incubation than trans-1,
suggesting faster and/or stronger untwisting. Furthermore, a reversion
of this retardation (probably caused by counter-twisting from the neg-
atively supercoiled through the untwisted to the positive supercoiled
state) is already observable after 30 min exposure to cis-1, but not
before 2 h exposure to trans-1. A similar dependence on geometric
isomerismapplies to thepair cis-3/trans-3. However, upon 3 h exposure
to trans-3 the plasmid becomes immobile and remains in the starting
well during electrophoresis. This might be caused by interhelical
cross-linking of plasmids to larger aggregates, which are not able
to enter the separation gel. Remarkably, cationic species trans-5–7
(bearing N-donor ligands only) also exhibit a capacity of altering DNA
secondary structure, even though the lack of readily exchangeable
ligandswould suggest that DNA interaction of these compounds should
primarily be of an electrostatic kind.
Generally, there is nodirect correlation between the cytotoxicity and
the alteration of dsDNA for most of the drugs with regard to time
required and the extent of the shift. The cytotoxicity of complexes
trans-4,5,6 increases with steric hindrance of the substituent R and
partially correlates with the ability of altering DNA secondary structure.
The most cytotoxic of these complexes (trans-5,6) were shown to exert
faster and stronger effects on DNA, while the least cytotoxic (trans-4)
does not have any signiﬁcant impact on the secondary structure of plas-
midDNA.Weak impact on plasmidDNAmay explain the lower cytotox-
icity of trans-7 and trans-4 compared to the other cationic complexes. In
the case of trans-7, it might be due to steric hindrance in interactingwith0
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Fig. 3. Cellular accumulation of cis-4, trans-4 (50 μM, 2 h exposure) in non-adherent
SW480 cells compared to the cisplatin/transplatin couple.DNA rather than the extent of cellular uptake,which is similar to both the
weakly cytotoxic trans-4 and rather cytotoxic trans-6.
4. Discussion
Compounds cis-1–6 and trans-1–8 belong to the new class of poten-
tial anticancer drugs based on guanidine (or, in a broader sense,
amidine) platinum(II) complexes. For many of these amidine species,
it was reliably shown that the cytotoxic activity of trans-complexes is
comparable or superior to that of the corresponding cis-isomers
[28–30]. Moreover, a similar dependence of cytotoxicity on geometric
isomerism was observed in the case of bis(oxime)platinum(II) speciestrans-5 trans-4
15’ 30’ 2h M
trans-7
15’ 30’ 2h
cis-4
15' 30’ 2h 15’ 30’ 2h C1
cis-6 trans-6
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Fig. 4. Mobility of the plasmid pUC19 after the exposure to 100 μM of different cis-/
trans- conﬁgured compounds. C —control, M —marker. Bright bands correspond to
the supercoiled form (SC) of the plasmid, whereas bands of the open circular (OC)
form are mostly too weak to allow interpretation.
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The bis(oxime) platinum complexes, structurally related to the gua-
nidine complexes, albeit bearing different N-donor organic ligands,
exhibit a very similar cytotoxicity pattern. The trans-conﬁgured neutral
bis(oxime) complexes are mostly superior in cytotoxicity to their cis-
congeners, while the cytotoxic potency of trans-conﬁgured cationic
bis(oxime) complexes increases with the bulkiness of the substituent
R. Similarly, there is a correlation between the cytotoxic potency of
the guanidine compounds and the steric hindrance of the variable
substituent R on the guanidine ligand. Cytotoxicities of the cationic
complexes are in some cases comparable to those of the corresponding
neutral complexes, despite the lack of distinctly labile ligands. The cyto-
toxic potencies of the tested complexes are inferior to that of cisplatin,
but many of them have IC50 values in the same order of magnitude as
carboplatin, another clinically active, approved platinum-based drug
(compare with Ref. [31]).
The behavior of cationic trans-6, containing only N-donor ligands, is
the most surprising with its high cytotoxicity comparable to that of the
neutral species cis-/trans-1–3, which contain two easily exchangeable
chlorido ligands. Both cellular accumulation and impact on DNA of
trans-6 are discrepant from those of neutral trans-congeners (trans-
1,3), raising the question whether this compound acts by a different
mechanism. The presence of the N–H moieties in guanidine complexes
entails pronounced abilities for various types of complementary H-
bonding interactions when approaching DNA, which may in connection
with coordinative binding lead to the formation of new types of adducts.
A high cytotoxic potencywas already shown for several similar examples
of double charged cationic amidine compounds by other authors [18,30].
To interpret the cellular accumulation results, several important
aspects have to be taken into account. (i) On the one hand, the rotation-
al symmetry of the trans-conﬁgured complexes implies the lack of
polarity, making them more lipophilic. Thereby, the neutral trans-
compounds probably have a higher ability to penetrate lipid mem-
branes, which is consistent with their higher cellular accumulation
observed experimentally. On the other hand, the cis-complexes possess
a pronounced polarity, lower lipophilicity and apparently lower cellular
permeability as a consequence. (ii) Another important difference
between the cis- and trans-complexes is their three-dimensional geom-
etry. While trans-complexes maintain the planar structure in solution,
steric hindrance of the adjacent ligands in the cis-complexes can force
their rotation out of the coordination plane. The planar structure is ste-
ricallymore favorable for passage throughmembranes. (iii) The cationic
am(m)ine complexes are kinetically inert, and the ligands can be hard-
ly exchanged with H2O. Taking all these points into account, the
higher cellular accumulation of the cis-conﬁgured cationic guanidine
complexes in comparison with their trans-isomers is unexpected and
requires further investigation. Concerning the difference in accumula-
tion of complexes featuring the same geometry, we suggest that the
permeability for complexes with more sterically encumbered substitu-
ents R is higher due to their pronounced lipophilicity.
Overall, nine of ten studied complexes were shown to be capable of
altering the DNA secondary structure strongly (most likely by cross-
linking), indicating DNA to be a possible target for the guanidine
platinum(II) species. In both pairs of neutral complexes (cis/trans-1,3),
the velocity and/or extent of structural changes imposed on plasmid
DNA is dependent on the geometry of the complex. In accordance
with the previously reported behavior of dichlorobis(acetoxime)
platinum(II) complexes but in contrast to that of cis-/transplatin [10],
the cis isomers are more effective in this respect. Steric constraints on
platinum–DNA interactions imposed by the larger guanidine ligands
(or acetoxime ligands, both as compared to ammine) might be a reason
for slower kinetics of DNA binding in the case of trans-isomers. For
the surprisingly strong impact of the cationic complexes trans-5 and
trans-6 (containing only N-donor ligands supposed to be stably coordi-
nated) on DNA secondary structure, there is no obvious explanation,
however.5. Conclusions
Aseries of guanidineplatinum(II) complexes cis-/trans-[PtX2(RCN)2](Cl2)
(R = NMe2, NEt2, NC5H10; X = NH3, Cl; cis-/trans-1–6), was extendedwith
two novel compounds, viz. trans-[Pt(NH2Me)2{NH=C(NHMe)NR}2](Cl)2
(R = NEt2, NC5H10) (trans-7,8). Structure–activity relationships were
inferred from bioanalytical experiments. In vitro cytotoxicity tests in
two human cancer cell lines, CH1 (cisplatin-sensitive) and SW480
(intrinsically cisplatin-resistant), conﬁrmed that the cytotoxicity of
the trans-conﬁgured complexes is, in some cases, comparable or higher
than that of the cis-congeners in contrast to the behavior of cisplatin/
transplatin. Substantial cytotoxicity was revealed for cationic com-
pound trans-6, despite the lack of distinctly labile ligands. Cellular accu-
mulation was shown to be dependent on geometrical isomerism of the
compounds, favoring the higher accumulation of the trans-conﬁgured
neutral trans-[PtCl2{NH=C(NH2)R}2] and the cis-conﬁgured cationic
cis-[Pt(NH3)2{NH=C(NH2)R}2](Cl)2 (R = NMe2, NC5H10) complexes
over their counterparts. Guanidine species trans-1,3,5,6,7 and cis-
1,3,4,6 were shown to alter DNA secondary structure to a different
extent and, considering cellular accumulation and cytotoxicity data,
DNA can be suggested as a main target. Further investigations of DNA
interactions (and other potential intracellular targets) may shed some
light on themode of action of these compounds. A better understanding
of themode of action of amidine platinum(II) antitumor agents, may, in
turn, help to rationally modify their chemical and biological properties
in order to optimize their anticancer activity.
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